http://www.lsis.com/goto/r7/rss 2010-06-23T11:10:05+01:00 text/html http://www.businesswire.com Business Wire http://www.lsis.com/goto/v7/%3B%97f%FB%1Cu%7C%7E WALTHAM, Mass.-(BUSINESS WIRE)-ImmunoGen, Inc. (Nasdaq: IMGN), a biopharmaceutical company that develops targeted anticancer therapeutics, today announced the promotion to vice president of two executive directors Godfrey Amphlett, Ph.D., and Robert J. Lutz, Ph.D. who have played central roles in establishing ImmunoGen s highly successful product development capabilities. These functions complement the Company s strong research capabilities in ImmunoGen s advancement of its own novel anticancer compounds and the industry-leading target-to-commercial product expertise the Company provides to its partners. ImmunoGen has transitioned from being an organization with strong research to one (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/goto/v7/%3B%97f%FB%1Ctys CAMBRIDGE, Mass. and CARLSBAD, Calif.-(BUSINESS WIRE)-Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY): We and Isis congratulate Regulus on forming this important new alliance with sanofi-aventis. Regulus stands as the leader in the emerging field of microRNA therapeutics, and this new partnership reflects the high level of interest across the pharmaceutical industry for innovative medicines based on this new biology New Partnership Validates Alnylam and Isis Strategy for Shareholder Value Creation Regulus, Alnylam and Isis to Host Conference Call Webcast to Discuss Regulus-Sanofi-aventis Collaboration on June 22, 2010 at 8:30 a.m. ET (5:30 a.m. PT) Alnylam Pharmaceuticals, Inc. (Nasdaq: (…) text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/goto/v7/%3B%97f%FB%12uvs Over the past few years a number of components of the PI3K/mTOR pathway have been the subject of intense drug discovery activities both in pharmaceutical companies and in academia. This review article summarizes progress made in the identification and development of allosteric and ATP-competitive kinase inhibitors of mTOR and their potential therapeutic use in oncology. |-| Bioorg Med Chem Lett. |-| García-Echeverría C. |-| Oncology Drug Discovery, Sanofi-Aventis, 13 Quai Jules Guesde, 94400 Vitry-sur-Seine, France. text/html http://www.biospace.com BioSpace http://www.lsis.com/goto/v7/%3B%97f%FB%10%7Dy%7D CARLSBAD, Calif.-(BUSINESS WIRE)-Regulus Therapeutics Inc. and sanofi-aventis (EURONEXT: SAN and NYSE: SNY) announced today that they have entered into a global, strategic alliance to discover, develop, and commercialize microRNA therapeutics. The alliance represents the largest microRNA partnership formed to date, valued at potentially over $750 million, and includes a $25 million upfront fee, a $10 million future equity investment subject to mutual agreement on company valuation, and annual research support for three years with the option to extend two additional years. The alliance will initially focus on the therapeutic area of fibrosis. Regulus and sanofi-aventis will collaborate on (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/goto/v7/%3B%97f%FB%11u%7D%7F SOUTH SAN FRANCISCO, Calif.-(BUSINESS WIRE)-Exelixis, Inc. (Nasdaq:EXEL) will provide an update on its collaboration with Bristol-Myers Squibb Company for XL184 on Monday, June 21, 2010 before the markets open. The announcement will be followed by a live webcast at 5:00 a.m. PT/ 8:00 a.m. ET. The webcast may be accessed in the Event Calendar page under Investors at http:/www.exelixis.com. An audio replay of the webcast will be available until 11:59 p.m ET/ 8:59 p.m. PT on July 5, 2010. Access numbers for the replay are: 888-286-8010 (domestic) and 617-801-6888 (international), and the passcode is 21140740. About Exelixis Exelixis, Inc. is a development-stage biotechnology company (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/goto/v7/%3B%97f%FB%11txy CAMBRIDGE, Mass.-(BUSINESS WIRE)-Dyax Corp. (NASDAQ: DYAX) and Defiante Farmaceutica S.A., a subsidiary of the pharmaceutical company Sigma-Tau SpA (Sigma-Tau), announced today a strategic partnership to develop and commercialize subcutaneous DX-88 (ecallantide) for the treatment of hereditary angioedema (HAE) and other therapeutic indications throughout Europe, North Africa, Middle East and Russia. Dyax retains its rights to subcutaneous DX-88 in other territories, including the U.S., where DX-88 has been approved by the U.S. Food and Drug Administration (FDA) and is marketed as KALBITOR (ecallantide) for the treatment of acute attacks of HAE in patients 16 years of age and older. (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/goto/v7/%3B%97f%FB%11t%7Ex SOUTH SAN FRANCISCO, Calif.-(BUSINESS WIRE)-Exelixis, Inc. today announced that it has regained full rights to develop and commercialize XL184. Exelixis and Bristol-Myers Squibb Company (BMS) entered into a global development collaboration for XL184, the clinically most advanced MET inhibitor, in December 2008. Under the agreement, BMS and Exelixis had originally agreed to certain clinical development plans, and Exelixis maintained key rights regarding timing and funding of current and future clinical trials. Given the recent progress of BMS wholly-owned oncology pipeline and positive data generated by XL184, Exelixis and BMS were not able to align on the scope, breadth and pace of the (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/goto/v7/%3B%97f%FB%11z%7C%7E SOUTH SAN FRANCISCO, Calif.-(BUSINESS WIRE)-Exelixis, Inc. (Nasdaq:EXEL) will provide an update on its collaboration with Bristol-Myers Squibb Company for XL184 on Monday, June 21, 2010 before the markets open. The announcement will be followed by a live webcast at 5:00 a.m. PT/ 8:00 a.m. ET. The webcast may be accessed in the Event Calendar page under Investors at http:/www.exelixis.com. An audio replay of the webcast will be available until 11:59 p.m ET/ 8:59 p.m. PT on July 5, 2010. Access numbers for the replay are: 888-286-8010 (domestic) and 617-801-6888 (international), and the passcode is 21140740. About Exelixis Exelixis, Inc. is a development-stage biotechnology company (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/goto/v7/%3B%97f%FB%14%7E%7Cx DUBLIN-(BUSINESS WIRE)-Research and Markets (http:/www.researchandmarkets.com/research/033170/the_russian_pharma) has announced the addition of the "The Russian Pharmaceutical Market Outlook to 2014: Policy Environment, Market Structure, Competitive Landscape, Growth Opportunities" report to their offering. The Russian Pharmaceutical Market Outlook to 2014: Policy Environment, Market Structure, Competitive Landscape, Growth Opportunities Russias well educated and low cost workforce is one of the main attraction for investors all over the world. According to recent statistics, Russia's population (which is currently about 141m) is steadily declining at a rate of around 0.4%. Thus, the (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/goto/v7/%3B%97f%FC%12%7B%7Cs BNET - As the July 4 holiday looms in the U.S., Sanofi-Aventis (SNY) employees aren t dreaming of barbecues, fireworks and a day off work they re worrying about layoffs. Sanofi has used Easter this year, Christmas and July 4 in 2009, and Thanksgiving in 2008 to announce mass layoffs. So when holidays loom, Sanofi workers sweat. text/html http://www.ncbi.nlm.nih.gov NCBI PubMed http://www.lsis.com/goto/v7/%3B%97f%FC%10yy%7D From an azaindole lead, identified in high throughput screen, a series of potent bis-azaindole inhibitors of IGF1-R have been synthesized using rational drug design and SAR based on a in silico binding mode hypothesis. Although the resulting compounds produced the expected improved potency, the model was not validated by the co-crystallization experiments with IGF1-R. |-| Chem Biol Drug Des. |-| Nemecek C, Metz WA, Wentzler S, Ding FX, Venot C, Souaille C, Dagallier A, Maignan S, Guilloteau JP, Bernard F, Henry A, Grapinet S, Lesuisse D. |-| Medicinal Chemistry, Sanofi-aventis, 13 Quai Jules Guesde, 94300 Vitry-sur-Seine, France. text/html http://www.biospace.com BioSpace http://www.lsis.com/goto/v7/%3B%97f%FD%1C%7B%7Cx Bloomberg - Sanofi-Aventis SA, France s biggest drugmaker, plans further expense reductions in areas such as marketing to offset lower revenue that s resulting from health- care reforms in Europe. text/html http://www.marketwire.com Marketwire http://www.lsis.com/goto/v7/%3B%97f%FD%11xvs Highlighted Links http:/www.businessgrouphealth.org WASHINGTON, DC-(Marketwire - June 14, 2010) - A record number of U.S. employers were honored today by the National Business Group on Health for their continuing commitment to promoting healthy work environments and encouraging workers to choose healthier lifestyles. A total of 66 large employers, including 13 first-time winners, were presented with "2010 Best Employers for Healthy Lifestyles" awards at the Business Group's Institute on Innovation in Workforce Well-being Leadership Summit held in Washington, DC. "Employers all across the nation are recognizing just how important a healthy workplace and a healthy workforce are to (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/goto/v7/%3B%97f%FD%11%7F%7Es DUBLIN-(BUSINESS WIRE)-Research and Markets (http:/www.researchandmarkets.com/research/86b7d0/opportunities_in_e) has announced the addition of the "Opportunities in Emerging Pharma Markets: Strategies for optimizing growth in key regions and therapeutic areas" report to their offering. Opportunities in Emerging Pharma Markets: Strategies for optimizing growth in key regions and therapeutic areas Pharmaceuticals, Generics, Vaccines, OTCs, Hepatitis and HIV/AIDS agents and Biosimilars appropriate for the Emerging markets. Other companies still seeking alliances are identified, as well as those that appear to be potential generic and Biosimilar supply partners. This report provides market (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/goto/v7/%3B%97f%FD%11%7Ew%7F ALBANY, N.Y.-(BUSINESS WIRE)-AMRI (NASDAQ: AMRI) today announced that its motion for a preliminary injunction to prevent Dr. Reddy s Laboratories, Ltd. and Dr. Reddy s Laboratories, Inc. (Dr. Reddy s) from the commercial distribution of generic versions of Allegra-D 24 Hour (fexofenadine HCl 180 mg and pseudoephedrine HCl 240 mg) Extended-Release Tablets in the Unites States has been granted. We are encouraged by the judge s ruling On June 14, 2010, US District Court Chief Judge Garrett E. Brown, Jr., District of New Jersey, issued the preliminary injunction based on a March 22, 2010 motion filed by AMRI and sanofi-aventis U.S. LLC, in response to the March 17, 2010 approval of Dr. Reddy (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/goto/v7/%3B%97f%FD%11%7Exs WALTHAM, Mass.-(BUSINESS WIRE)-Phase Forward (NASDAQ: PFWD), a leading provider of data management solutions for clinical trials and drug safety, today announced its Central Coding ¢ application has become the first product to achieve certification by the Uppsala Monitoring Center (UMC). Launched today ( œUppsala Monitoring Centre Launches Software Certification Program for WHO Drug Dictionary Enhanced ), UMC s new certification is designed to help software developers quickly and easily integrate the WHO Drug Dictionary Enhanced. The WHO Drug Dictionary Enhanced is the world s most comprehensive dictionary of medicinal product information and the de facto standard for coding (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/goto/v7/%3B%97f%FD%16uy%7D HYDERABAD, India-(BUSINESS WIRE)-Dr. Reddy s Laboratories (NYSE: RDY) announced today that the U.S. District Court of New Jersey has granted sanofi-aventis and Albany Molecular Research s motion for a Preliminary Injunction. The motion is related to Dr. Reddy s abbreviated new drug application to market its generic version of Allegra D24 (fexofenadine hydrochloride / pseudoephedrine hydrochloride 180 mg / 240 mg extended release tablet). Dr. Reddy s strongly disagrees with the Court s decision and intends to appeal. Allegra D24 is a registered trademark of sanofi-aventis. Disclaimer This press release includes forward-looking statements, as defined in the U.S. Private Securities (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/goto/v7/%3B%97f%FE%1Cu%7B%7E SCHAUMBURG, Ill.-(BUSINESS WIRE)-Fresenius Kabi Pharmaceuticals Holding, Inc., (NASDAQ: APCVZ) announced today that APP Pharmaceuticals will immediately begin marketing Oxaliplatin Injection (liquid) in the U.S. The U.S. Food and Drug Administration granted approval to market Oxaliplatin Injection in two dosage strengths to Fresenius Kabi Oncology Limited (NSE: FKONCO) (BSE: 532545). APP Pharmaceuticals and Fresenius Kabi Oncology Limited are members of the Fresenius Kabi Group of companies. APP currently markets the lyophilized product, Oxaliplatin for Injection, 50 mg and 100 mg. This approval enables APP to offer its customers a choice between the lyophilized product that APP (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/goto/v7/%3B%97f%FE%1Cu%7F%7F SOUTH SAN FRANCISCO, Calif.-(BUSINESS WIRE)-Exelixis, Inc. (NASDAQ: EXEL) announced today that George A. Scangos, PhD, the company s president and chief executive officer, will present at the Goldman Sachs 31st Annual Global Healthcare Conference at 1:20 p.m. PDT / 4:20 p.m. EDT on Tuesday June 15, 2010 in Los Angeles. Dr. Scangos will discuss the company s corporate strategy and development pipeline, and provide a general business update. The event will be webcast and may be accessed in the Event Calendar page under Investors at http:/www.exelixis.com. About Exelixis Exelixis, Inc. is a development-stage biotechnology company dedicated to the discovery and development of novel small (…) text/html http://www.marketwire.com Marketwire http://www.lsis.com/goto/v7/%3B%97f%FE%12yzy Highlighted Links Nat'l Employee Wellness Month Virgin HealthMiles BOSTON, MA and WASHINGTON, DC and SCOTTSDALE, AZ-(Marketwire - June 10, 2010) - In tandem with June's National Employee Wellness Month, Virgin HealthMiles, the Strategies to Overcome and Prevent (STOP) Obesity Alliance and the Institute for Health and Productivity Management have developed a collection of wellness resources and tools designed to help employers and employees create healthier workplaces. The collection of resources (featured at www.nationalemployeewellnessmonth.com) includes easy-to-implement workplace wellness program ideas, case studies of corporate and employee wellness innovators, whitepapers about (…) text/html http://www.medicalnewstoday.com Medical News Today http://www.lsis.com/goto/v7/%3B%97f%FE%12%7F%7Dx Counterfeit and unlicensed medicines, along with controlled drugs to the street value of approximately £150,000, were seized by the MHRA yesterday as part of a simultaneous raid on six locations across London, and two in Yorkshire with the assistance of local police. Six people in the UK believed to be linked to a gang in Asia were arrested in connection with the illegal sale and supply of a range of medicinal products, most of which are suspected to be counterfeit. Information was initially passed to the MHRA by pharmaceutical manufacturers Pfizer, Lilly and Sanofi-aventis. MHRA Head of Intelligence Nimo Ahmed said, "Large boxes containing counterfeit and unlicensed medicines together (…) text/html http://www.medicalnewstoday.com Medical News Today http://www.lsis.com/goto/v7/%3B%97f%FE%12%7Ev%7B Micromet, Inc. (Nasdaq: MITI), a biopharmaceutical company focused on the development and commercialization of next-generation antibodies for the treatment of cancer, today announced the presentation of updated interim results from a Phase 1 trial of the Company's BiTE antibody MT110 in patients with advanced solid tumors. MT110 is designed to direct a patient's T cells, the immune system's most potent killer cells, against cancer cells that express the epithelial cell adhesion molecule (EpCAM). Professor Walter Fiedler, University Hospital Hamburg-Eppendorf, Germany and the study's principal investigator, presented the data today at the American Society of Clinical Oncology Annual Meeting (…) text/html http://www.medicalnewstoday.com Medical News Today http://www.lsis.com/goto/v7/%3B%97f%FE%12%7E%7Dz The growing use of insulin delivery devices such as pens and pumps may help individuals with diabetes optimize blood glucose control and minimize their risk for chronic health problems associated with diabetes, as described in a Special Supplement to Diabetes Technology & Therapeutics, a peer-reviewed journal published by Mary Ann Liebert, Inc. The issue is available free online (http:/www.liebertpub.com/dia). "Improved delivery devices for insulin treatment have increased patient compliance and acceptance of an intensive insulin strategy," which can result in significant reductions in long-term complications associated with poorly controlled type 1 and type 2 diabetes, says Satish Garg, (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/goto/v7/%3B%97f%FE%13uw%7C DUBLIN-(BUSINESS WIRE)-Research and Markets (http:/www.researchandmarkets.com/research/122efb/looking_at_the_can) has announced the addition of the "Looking at the Cancer Therapy Market" report to their offering. Cancer is a disease characterized by a population of cells that grow and divide without respect to normal limits, invade and destroy adjacent tissues, and may spread to distant anatomic sites through a process called metastasis. These life-threatening, malignant properties of cancers differentiate them from benign tumors, which are self-limited in their growth and do not invade or metastasize. Cancer may affect people at all ages, but risk for the more common varieties tends to (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/goto/v7/%3B%97f%FE%13uwy DUBLIN-(BUSINESS WIRE)-Research and Markets (http:/www.researchandmarkets.com/research/3ff3ce/pharmaceutical_ind) has announced the addition of the "Pharmaceutical Industry in Mexico" report to their offering. Over the past decade, pharmaceutical companies have pushed the scientific envelope, working at the cellular and molecular levels to dramatically advance the treatment of disease. Mexico's pharmaceutical policy environment is in a period of rapid evolution, with simultaneous policy development, refinement and ongoing implementation. This handicaps Mexico's efforts to achieve policy goals efficiently at the present time, and also makes policy assessment and even accurate description (…) text/html http://www.bionity.com Bionity.com http://www.lsis.com/goto/v7/%3B%97f%FE%15%7By%7C 10.06.2010 - Sanofi Pasteur, the vaccines division of sanofi-aventis Group, announced the signature with Vivalis of a commercial license and collaboration agreement for the discovery and development of fully human monoclonal antibodies against several infectious diseases. Under the terms of the agreement, Sanofi Pasteur and its affiliates acquire exclusive access to Vivalis platform for the discovery of fully human monoclonal antibodies targeting clinically significant infectious diseases, and will obtain worldwide exclusive development and commercialization rights for the discovered antibodies. "Passive immunization can be a powerful treatment option against infectious diseases in (…) text/html http://www.marketwire.com Marketwire http://www.lsis.com/goto/v7/%3B%97f%FE%15%7Bxy All public secondary students throughout BC will now have access to lifesaving CPR skills thanks to a donation of more than 3,500 CPR mannequins from AstraZeneca Canada, sanofi-aventis and Pfizer Canada. The donation of $500,000 goes to the ACT Foundation, a national charitable organization with a mandate to establish the CPR program in secondary schools across Canada. The donation extends the program to more than 80 additional BC schools bringing the total coverage to over 260 schools in BC. It also increases the number of BC students trained from 34,000 a year to 48,000 a year. For more information please visit www.actfoundation.ca. Photo by Kevin Hill. RICHMOND, BRITISH (…) text/html http://www.marketwire.com Marketwire http://www.lsis.com/goto/v7/%3B%97f%FE%15%7B%7Cr RICHMOND, BRITISH COLUMBIA-(Marketwire - June 8, 2010) - Thanks to a $500,000 contribution from pharmaceutical leaders AstraZeneca Canada, Pfizer Canada and sanofi-aventis, the lifesaving ACT High School CPR Program opportunity can now be extended to all BC public secondary schools. Currently, 180 BC public secondary schools have been set up with ACT High School CPR Program. Thanks to this generous donation, over 80 more BC public secondary schools can now receive the program. With this new support the number of students trained each year is expected to jump from 34,000 to 48,000 and teachers trained will go from 675 to over 1,000. The funds will purchase and distribute 3,555 CPR (…) text/html http://www.sciencedaily.com ScienceDaily http://www.lsis.com/goto/v7/%3B%97f%FE%15zy%7B ScienceDaily (June 8, 2010) The growing use of insulin delivery devices such as pens and pumps may help individuals with diabetes optimize blood glucose control and minimize their risk for chronic health problems associated with diabetes, as described in a Special Supplement to Diabetes Technology & Therapeutics. See Also: Health & Medicine Diabetes Hormone Disorders Personalized Medicine Hypertension Chronic Illness Wounds and Healing Reference Blood sugar Diabetes mellitus type 2 Diabetes mellitus type 1 Hyperglycemia Improved delivery devices for insulin treatment have increased patient compliance and acceptance of an intensive insulin strategy, which can result in significant (…) text/html http://www.medicalnewstoday.com Medical News Today http://www.lsis.com/goto/v7/%3B%97f%FE%15z%7Ds Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) announced positive results from a study assessing a new lower-volume injection of Copaxone (glatiramer acetate) containing the currently approved dose in half the injection volume. The SONG study ('Study of New Glatiramer Acetate Formulation') explored the safety and tolerability of a 20mg/0.5mL injection of Copaxone versus the current formulation of 20 mg/1.0mL. These findings were presented at the 24th Annual meeting of the Consortium of Multiple Sclerosis Centers (CMSC) in San Antonio, Texas. "Copaxone has proven long-term efficacy, safety and tolerability with more than one million patient years of treatment," said Dr. Ronald (…) text/html http://www.medicalnewstoday.com Medical News Today http://www.lsis.com/goto/v7/%3B%97f%FE%15ywz VIVALIS (NYSE Euronext: VLS) announced the signature with Sanofi Pasteur, the vaccines division of sanofi-aventis Group (Euronext: SAN and NYSE: SNY), of a commercial license and collaboration agreement for the discovery and development of fully human monoclonal antibodies against several infectious diseases targets. Under the terms of the agreement, Sanofi Pasteur and its affiliates acquire exclusive access to the Humalex platform for the discovery of human monoclonal antibodies targeting several clinically significant infectious diseases, and will obtain worldwide exclusive development and commercialization rights for the discovered antibodies. The HUMALEX platform is a potent (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/goto/v7/%3B%97f%FE%15x%7E%7F TRENTON, N.J.-(BUSINESS WIRE)-BioNJ, New Jersey s trade association for the biotechnology industry, will hold its 2010 BioPartnering Conference on June 14 and 15 at the Westin Princeton at Forrestal Village, in Princeton, NJ. New Jersey s only biopartnering conference, the two-day meeting will provide a valuable opportunity for biotechnology and pharmaceutical companies located in New Jersey and beyond to discuss partnerships, licensing agreements and other collaborative efforts, and will include keynote speakers from Johnson & Johnson, Merck & Co., Inc, Pfizer, sanofi-aventis US and Defined Health. This is a significant opportunity for New Jersey s biotechnology firms to network with (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/goto/v7/%3B%97f%FF%12yz%7C Bloomberg - Sanofi-Aventis SA achieved œstunning  results in an ongoing human trial for its novel cancer drug aimed at breast and lung tumors, Chief Executive Officer Chris Viehbacher said. text/html http://www.biospace.com BioSpace http://www.lsis.com/goto/v7/%3B%97f%FF%12xyx GLOSTRUP, DENMARK-(Marketwire - June 08, 2010) - Copenhagen, 08 June 2010 Announcement no. 5, 2010 Zealand Pharma A/S ("Zealand Pharma" or "the Company") Zealand Pharma Announces An Extension of The Lixisenatide Global Licensing Agreement with sanofi-aventis for Type-2 Diabetes Zealand Pharma A/S, the biopharmaceutical company dedicated to the discovery and development of innovative peptide-based drugs, is pleased to announce that the global licensing agreement with sanofi-aventis has been amended to provide for the development and commercialization of Lixisenatide (AVE0010/ZP10) in combination with Lantus, sanofi-aventis' recombinant human insulin analog. Lixisenatide is a (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/goto/v7/%3B%97f%FF%12xxr TRENTON, N.J.-(BUSINESS WIRE)-BioNJ, New Jersey s trade association for the biotechnology industry, will hold its 2010 BioPartnering Conference on June 14 and 15 at the Westin Princeton at Forrestal Village, in Princeton, NJ. New Jersey s only biopartnering conference, the two-day meeting will provide a valuable opportunity for biotechnology and pharmaceutical companies located in New Jersey and beyond to discuss partnerships, licensing agreements and other collaborative efforts, and will include keynote speakers from Johnson & Johnson, Merck & Co., Inc, Pfizer, sanofi-aventis US and Defined Health. text/html http://www.biospace.com BioSpace http://www.lsis.com/goto/v7/%3B%97f%FF%12x%7B%7C NANTES, FRANCE-(Marketwire - June 08, 2010) - Highlighted Links companynewsgroup Home Page VIVALIS (NYSE Euronext: VLS) announced today the signature with Sanofi Pasteur, the vaccines division of sanofi-aventis Group (Euronext: SAN and NYSE: SNY), of a commercial license and collaboration agreement for the discovery and development of fully human monoclonal antibodies against several infectious diseases targets. Under the terms of the agreement, Sanofi Pasteur and its affiliates acquire exclusive access to the Humalex platform for the discovery of human monoclonal antibodies targeting several clinically significant infectious diseases, and will obtain worldwide exclusive development (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/goto/v7/%3B%97f%FF%12x%7Fr SCHAUMBURG, Ill., Jun 08, 2010 (BUSINESS WIRE) - APP Pharmaceuticals, Inc., a wholly owned subsidiary of Fresenius Kabi Pharmaceuticals Holding, Inc., /quotes/comstock/15*!apcvz/quotes/nls/apcvz (APCVZ 0.15, +0.00, +2.74%) announced today it received approval from the U.S. Food and Drug Administration to market Oxaliplatin for Injection (lyophilized), 50 mg and 100 mg. APP currently markets Oxaliplatin for Injection (lyophilized) under a previously approved ANDA for Fresenius Kabi Oncology Limited (NSE: FKONCO, BSE: 532545). APP Pharmaceuticals and Fresenius Kabi Oncology Limited are members of the Fresenius Kabi Group of companies. Oxaliplatin for Injection is therapeutically equivalent (…) text/html http://www.bionity.com Bionity.com http://www.lsis.com/goto/v7/%3B%97f%FF%12x%7F%7E 08.06.2010 - Zealand Pharma A/S announced that the global licensing agreement with sanofi-aventis has been amended to provide for the development and commercialization of Lixisenatide (AVE0010/ZP10) in combination with Lantus, sanofi-aventis' recombinant human insulin analog. Lixisenatide is a Zealand-invented GLP-1 (glucagon-like-peptide-1) receptor agonist for the treatment of Type-2 Diabetes, and uses Zealand's proprietary SIP(TM) (structure inducing probe) peptide modification technology. In April 2010, sanofi-aventis reported positive Phase III results from the first of nine clinical studies within the Lixisenatide GetGoal Phase III program. Filing of Lixisenatide is expected to (…) text/html http://www.bionity.com Bionity.com http://www.lsis.com/goto/v7/%3B%97f%FF%12x%7Fy 08.06.2010 - Sanofi-aventis and Ascenta Therapeutics announced the signature of an exclusive global collaboration and licensing agreement on a number of compounds that could restore tumor cell apoptosis. These compounds inhibit the p53-HDM2 (Human Double Minute 2) protein-protein interaction, leading potentially to reactivation of p53 tumour suppressor functions and therefore enhancing current cancer treatments. Under this agreement, sanofi-aventis will receive an exclusive worldwide license to develop, manufacture and commercialize all compounds issued from this program. Two compounds, MI-773 and MI-519-64, are currently expected to enter preclinical development in 2010. Ascenta has (…) text/html http://www.marketwire.com Marketwire http://www.lsis.com/goto/v7/%3B%97f%FF%12%7Fv%7C RICHMOND, BRITISH COLUMBIA-(Marketwire - June 7, 2010) - DATE: Tuesday, June 8th, 2010 TIME: 10 a.m. WHERE: Richmond Secondary School 7171 Minoru Blvd Richmond, British Columbia V6Y 1Z3 WHAT: The ACT Foundation, along with AstraZeneca Canada, Pfizer Canada and sanofi-aventis will announce a major province-wide donation in support of the lifesaving ACT High School CPR Program. This announcement will feature a mock emergency where BC public secondary students will rescue a cardiac arrest victim using their CPR skills. As well, a class of 30 students will participate in a CPR training demonstration and more than 200 donated training mannequins, of the 3500 to be donated, will be on site. (…) text/html http://www.marketwire.com Marketwire http://www.lsis.com/goto/v7/%3B%97f%FF%12%7Fv%7F RICHMOND, COLOMBIE-BRITANNIQUE-(Marketwire - 7 juin 2010) - DATE : Mardi 8 juin 2010 HEURE : 10 h Oà : Richmond Secondary School 7171, boulevard Minoru Richmond (Colombie-Britannique) V6Y 1Z3 QUOI : La Fondation ACT ainsi que AstraZeneca Canada, Pfizer Canada et sanofi-aventis feront l'annonce d'un don important visant à soutenir le Programme de RCR au secondaire d'ACT dans l'ensemble de la province. Lors de cet événement, il y aura une simulation d'urgence durant laquelle des élèves du secondaire public de C.-B. mettront en pratique leurs connaissances en RCR en venant en aide à une victime d'un arrêt cardiaque. Aussi bien, une classe de 30 élèves participera à (…) text/html http://www.sciencedaily.com ScienceDaily http://www.lsis.com/goto/v7/%3B%97f%FF%12%7Fxx ScienceDaily (June 7, 2010) To the surprise of researchers at Mayo Clinic who led a national clinical trial, a targeted therapy that provides benefit to patients with metastatic colon cancer has failed to help patients with less advanced, stage III cancer. In fact, patients who used the agent, cetuximab, with chemotherapy had outcomes slightly inferior to patients treated with chemotherapy alone. See Also: Health & Medicine Colon Cancer Breast Cancer Lung Cancer Diseases and Conditions Cancer Prostate Cancer Reference Clinical trial Metastasis Hepatocellular carcinoma Breast cancer The phase III North Central Cancer Treatment Group (NCCTG) study, sponsored by the National Cancer Institute (…) text/html http://www.medicalnewstoday.com Medical News Today http://www.lsis.com/goto/v7/%3B%97f%FF%12%7Evr Pharmacoeconomic methods rank low as a decision influencer on formulary changes, according to a new survey released by the Society of Hospital Medicine (SHM) and the American Society of Health-System Pharmacists (ASHP). Respondents reported that only 13 percent of formulary system decisions made by Pharmacy and Therapeutics (P&T) committees in hospitals is influenced by pharmacoeconomic methods. The findings in the new report are based on a survey of 319 ASHP members that were either directors of pharmacy or members of ASHP's Pharmacy Practice Managers Section. Pharmacoeconomic methods evaluate the value of effects compared to the cost of pharmaceutical products when making decisions on (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/goto/v7/%3B%97f%FF%12%7Ezx CAMBRIDGE, Mass.-(BUSINESS WIRE)-Dyax Corp. (NASDAQ: DYAX) announced today the publication of results from its second Phase 3, placebo-controlled trial, known as EDEMA4, evaluating KALBITOR (ecallantide) for the treatment of acute attacks of hereditary angioedema (HAE). The results, published in the June 2010 issue of the Annals of Allergy, Asthma, and Immunology, indicate that KALBITOR is effective in ameliorating HAE attacks, resolving associated symptoms and preventing attack progression. KALBITOR, a selective plasma kallikrein inhibitor that was discovered and developed by Dyax, is available in the U.S. for the treatment of acute attacks of HAE in patients 16 years of age and older. (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/goto/v7/%3B%97f%FF%12%7Dvx WALTHAM, Mass.-(BUSINESS WIRE)-ImmunoGen, Inc. (Nasdaq: IMGN), a biopharmaceutical company that develops targeted anticancer therapeutics, today announced the presentation of the first clinical data for the Company s IMGN388 anticancer compound at the 2010 Annual Meeting of the American Society of Clinical Oncology (ASCO) being held in Chicago, IL. In this dose-escalation trial, IMGN388 has demonstrated favorable tolerability at the dose levels evaluated to date, and evidence of activity is being reported now that higher doses are starting to be evaluated. Dose escalation is continuing. We re encouraged by the clinical findings with IMGN388 œWe re encouraged by the clinical findings (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/goto/v7/%3B%97f%FF%12%7Dxy SOUTH SAN FRANCISCO, Calif.-(BUSINESS WIRE)-Exelixis, Inc. (NASDAQ: EXEL) announced today that Michael M. Morrissey, PhD, the company s president of research and development, will present at Jefferies 2010 Global Life Sciences Conference at 10:00 a.m. EDT / 7:00 a.m. PDT on Wednesday June 9, 2010 in New York. Mr. Morrissey will discuss the company s corporate strategy, development pipeline, and provide a general business update. The event will be webcast and may be accessed in the Event Calendar page under Investors at http:/www.exelixis.com. About Exelixis Exelixis, Inc. is a development-stage biotechnology company dedicated to the discovery and development of novel small molecule (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/goto/v7/%3B%97f%FF%12%7Dx%7B CHICAGO-(BUSINESS WIRE)-ASCO Abstract Number: CRA3507 - To the surprise of researchers at Mayo Clinic who led a national clinical trial, a targeted therapy that provides benefit to patients with metastatic colon cancer has failed to help patients with less advanced, stage III cancer. In fact, patients who used the agent, cetuximab, with chemotherapy had outcomes slightly inferior to patients treated with chemotherapy alone. It is difficult to understand how an agent that helps patients with metastatic cancer is not beneficial to those with less advanced disease. At this point we are focusing our efforts on identifying a biological explanation for these findings. VIDEO ALERT: Additional (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/goto/v7/%3B%97f%FF%12%7D%7B%7E IRVINE, Calif.-(BUSINESS WIRE)-Allergan, Inc. (NYSE: AGN) has received CEO Cancer Gold Standard ¢ accreditation, recognizing the organization s commitment to taking concrete actions to reduce the cancer risk of its employees and their families through screenings, early detection, and healthy changes in lifestyle and in the workplace. do something bold and venturesome about cancer within your own corporate families. William C. Weldon, chairman and chief executive officer of Johnson & Johnson, chairs the CEO Roundtable on Cancer, a nonprofit organization of cancer-fighting CEOs who created the CEO Cancer Gold Standard ¢, in collaboration with the National Cancer Institute, many of its (…) text/html http://www.businesswire.com Business Wire http://www.lsis.com/goto/v7/%3B%97f%FF%12%7Dz%7F SOUTH SAN FRANCISCO, Calif.-(BUSINESS WIRE)-Exelixis, Inc. (Nasdaq:EXEL) today reported updated interim data from three ongoing trials of XL147 (SAR245408), a selective, orally available small molecule inhibitor of phosphoinositide-3-kinase (PI3K). Activation of the PI3K pathway is a frequent event in human tumors, promoting cell proliferation, survival, and resistance to chemotherapy and radiotherapy. The pathway also has been implicated as a mediator of resistance to agents targeting epidermal growth factor receptor (EGFR) family members. The presentations will be made at the 2010 Annual Meeting of the American Society of Clinical Oncology, which is being held June 4-8 in Chicago. (…) text/html http://www.biospace.com BioSpace http://www.lsis.com/goto/v7/%3B%97f%FF%12%7C%7Dz SOUTH SAN FRANCISCO, Calif.-(BUSINESS WIRE)-Exelixis, Inc. (Nasdaq: EXEL) today reported updated interim data from three ongoing trials of XL765 (SAR245409), an orally available small molecule inhibitor of phosphoinositide-3-kinase (PI3K) and mTOR. Activation of the PI3K pathway is a frequent event in human tumors, promoting cell proliferation, survival, and resistance to chemotherapy and radiotherapy. The pathway also has been implicated as a mediator of resistance to agents targeting epidermal growth factor receptor (EGFR) family members. The presentations will be made at the 2010 Annual Meeting of the American Society of Clinical Oncology, which is being held June 4-8 in Chicago. (…)